Evidence map›Paper›PMID 33976146›Full record

ArticleNature communications2021

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.

Xuqing Zhang, Mengyao Luo, Shamael R Dastagir, Mellissa Nixon, Annie Khamhoung, Andrea Schmidt, Albert Lee, Naren Subbiah, Douglas C McLaughlin, Christopher L Moore and 12 more

Open access · goldAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Xuqing ZhangRubius Therapeutics, Inc., Cambridge, MA, USA.
Mengyao LuoRubius Therapeutics, Inc., Cambridge, MA, USA.
Shamael R DastagirRubius Therapeutics, Inc., Cambridge, MA, USA.
Mellissa NixonRubius Therapeutics, Inc., Cambridge, MA, USA.
Annie KhamhoungRubius Therapeutics, Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1679-7125
Andrea SchmidtRubius Therapeutics, Inc., Cambridge, MA, USA.
Albert LeeRubius Therapeutics, Inc., Cambridge, MA, USA.
Naren SubbiahRubius Therapeutics, Inc., Cambridge, MA, USA.
Douglas C McLaughlinRubius Therapeutics, Inc., Cambridge, MA, USA.
Christopher L MooreRubius Therapeutics, Inc., Cambridge, MA, USA.
Mary GribbleRubius Therapeutics, Inc., Cambridge, MA, USA.
Nicholas BayhiRubius Therapeutics, Inc., Cambridge, MA, USA.
Viral AminRubius Therapeutics, Inc., Cambridge, MA, USA.
Ryan PepiRubius Therapeutics, Inc., Cambridge, MA, USA.
Sneha PawarRubius Therapeutics, Inc., Cambridge, MA, USA.
Timothy J LyfordRubius Therapeutics, Inc., Cambridge, MA, USA.
Vikram SomanRubius Therapeutics, Inc., Cambridge, MA, USA.
Jennifer MellenRubius Therapeutics, Inc., Cambridge, MA, USA.
Christopher L CarpenterRubius Therapeutics, Inc., Cambridge, MA, USA.
Laurence A TurkaRubius Therapeutics, Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2104-6967
Thomas J WickhamRubius Therapeutics, Inc., Cambridge, MA, USA.
Tiffany F ChenRubius Therapeutics, Inc., Cambridge, MA, USA. tiffany.chen@rubiustx.com.ORCID http://orcid.org/0000-0002-8089-1143
Rubius Therapeutics (United States) · US

Funding

Super-Resolution ImagingP30NS072030 · NINDS · HARVARD MEDICAL SCHOOL · PI REGEHR, WADE G · 2011 to 2020
$5.8M
NINDS NIH HHS P30 NS072030
6 · The paper itself

Abstract

Checkpoint inhibitors and T-cell therapies have highlighted the critical role of T cells in anti-cancer immunity. However, limitations associated with these treatments drive the need for alternative approaches. Here, we engineer red blood cells into artificial antigen-presenting cells (aAPCs) presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin (IL)-12. This leads to robust, antigen-specific T-cell expansion, memory formation, additional immune activation, tumor control, and antigen spreading in tumor models in vivo. The presence of 4-1BBL and IL-12 induces minimal toxicities due to restriction to the vasculature and spleen. The allogeneic aAPC, RTX-321, comprised of human leukocyte antigen-A*02:01 presenting the human papilloma virus (HPV) peptide HPV16 E7

Indexed as

4-1BB LigandAnimalsAntigen-Presenting CellsCell EngineeringCell Line, TumorCoculture TechniquesDisease Models, AnimalErythrocytesFemaleHistocompatibility Antigens Class IHLA-A2 AntigenHumansImmunotherapy, AdoptiveInterleukin-12Lymphocyte ActivationNeoplasms4-1BB LigandHistocompatibility Antigens Class IHLA-A*02:01 antigenHLA-A2 AntigenInterleukin-12oncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsTNFSF9 protein, human

Identifiers

PMID33976146
PMCPMC8113241
OpenAlexW3161476910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.